NCT07311564Phase 2Recruiting
A Study of LAD603 in Adults With Alopecia Areata
A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata
In the register
The register attaches this trial to LAD603 (Almirall), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Almirall, S.A.
- Participants (registry)
- 136
- Start
- December 2025
- Primary completion
- June 2027 (planned)
- Study completion
- November 2027 (planned)
- Last registry update
- May 2026
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: LAD603, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.